this 2nd day of May 2006. - signature- (Mr. Thanong Bidaya) Minister of Finance Chairman of the Securities and Exchange Commission Note: please note that the contents added in brackets [….] have only
เพ่ิมข้ึนเกิดจากเงินกูระยะยาวเพ่ือรองรับโครงการพลังงาน Project Finance และการออกหุน กูเพ่ือเปนเงินทุนหมุนเวียนในธุรกิจรวมถึงการปรับปรุงเคร่ืองจักรและอาคารโรงงาน จึงเรียนมาเพ่ือทราบ ขอแสดงความนับถือ บริษัท
Baht 497.34 million Baht 31.26 million 6.29 1.7 Finance cost Baht 215.23 million Baht 224.38 million Baht (9.15) million (4.08) 2. Operation performance for the year ended December 31 Item 2018 2017
% Administrative Expenses 14.7 8.2% 19.0 11.1% 4.3 29.3% Total Expenses 37.1 20.8% 43.3 25.2% 6.2 16.7% Earnings Before Interest and tax 9.8 5.5% 9.5 5.5% -0.3 -3.1% Finance Cost 13.3 7.5% 14.7 9.4% 1.4 10.5% Tax
capital increase of Baht 55 million. Please be informed accordingly. Sincerely yours, Miss Suwarin Konthong Executive Vice President of Account and Finance DOD Biotech Public Company Limited
debt ratio stemming from increased loans and lower shareholder equity, the ratio was nonetheless at comfortably low level. The interest coverage ratio (EBITDA / finance costs) decreased to 53.7x from
) (32,536) -10% Impairment of investment in subsidiary - - (3,723) - 100% Finance costs (28,569) (33,716) -15% (13,738) (19,474) -29% 4 THB’000 Consolidated ∆% Separate ∆% 1Q2019 1Q2018 1Q2019 1Q2018 Profit
Financial Statements is attached herewith for your acknowledgement and disseminating to investors accordingly. Yours Sincerely, ( Kamtorn Sila-On ) President Production and Finance S & P Syndicate Public
) 10.8% (146.1) (187.4) (41.3) 28.3% Operating Profit 190.4 217.7 27.3 14.4% 377.5 452.2 74.8 19.8% Finance Cost (30.6) (45.4) (14.8) 48.4% (58.3) (86.5) (28.2) 48.3% Tax Expenses (39.3) (35.1) 4.2 -10.7
last year. Finance Cost The Company and its subsidiaries had the financial cost 0.9 MB in Q2/2019 which decreased by 1.3 MB from Q2/2018 or 58.0 percent (2.2 MB in Q2/2018) Financial Status The overall